WashingtonAppointee overruled US drug agency scientists on teplizumab.
Acting drug-evaluation director Tracy Beth Høeg rejected staff scientists’ positive review; Sanofi exited Commissioner Makary’s fast-track voucher program in response.
Agency directors rarely review individual drugs; Makary himself has called political overrides of scientific staff a “disaster.”
Sources: STAT
WHAT TEPLIZUMAB ACTUALLY DOES
Teplizumab is a monoclonal antibody that binds CD3 on T cells, blunting the autoimmune attack that destroys insulin-producing beta cells. In stage-2 type 1 diabetes patients, a single 14-day course delays clinical onset by a median of about two years — the first disease-modifying therapy ever approved for T1D, cleared by the FDA in 2022.
HOW FDA REVIEW NORMALLY WORKS
A new drug application lands at the Center for Drug Evaluation and Research, where a multi-disciplinary team — medical officers, statisticians, pharmacologists, toxicologists — writes independent reviews. The division director signs off on the consensus. Center directors and the Commissioner almost never touch individual drug decisions; their job is policy, not adjudication.
THE BUMPERS DOCTRINE
FDA's institutional credibility rests on a 1962 statutory bargain: the agency, not Congress or the White House, decides whether a drug is safe and effective. The Kefauver-Harris Amendments — passed after thalidomide caused thousands of birth defects in Europe — gave career scientists insulating authority precisely so political pressure could not move approvals.
PRIORITY REVIEW VOUCHERS
FDA grants tradable vouchers — for rare pediatric, tropical, or material-threat drugs — that compress review time from ~10 months to ~6 months. Sponsors sell unused vouchers; recent transactions have cleared in the $100M range. Makary's expanded voucher program tied eligibility to broader policy goals, which is why pulling out is a costly signal.
WHY OVERRIDES ARE STRUCTURALLY RARE
When a political appointee overrules career staff, the next sponsor reads the signal: review outcomes are negotiable upward of the science. That degrades the value of every future approval — pharma's willingness to invest billions in trials depends on the rules being legible. Makary's own past warning about overrides is the textbook formulation of that risk.
THE EXIT AS LEVERAGE
A sponsor walking away from a flagship FDA program is unusual — drugmakers normally absorb friction quietly to preserve relationships. Sanofi's public exit converts a single-drug dispute into a credibility test for the voucher program itself, raising the cost of the override beyond this one decision.